Caisse Des Depots ET Consignations Takes $798,000 Position in Harrow, Inc. (NASDAQ:HROW)

Caisse Des Depots ET Consignations bought a new stake in Harrow, Inc. (NASDAQ:HROW - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 23,785 shares of the company's stock, valued at approximately $798,000. Caisse Des Depots ET Consignations owned about 0.07% of Harrow at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in shares of Harrow by 443.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock valued at $10,717,000 after purchasing an additional 194,480 shares during the last quarter. Barclays PLC lifted its holdings in Harrow by 301.9% in the third quarter. Barclays PLC now owns 52,593 shares of the company's stock valued at $2,365,000 after buying an additional 39,506 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Harrow by 195.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company's stock valued at $11,313,000 after acquiring an additional 166,602 shares during the last quarter. State Street Corp boosted its position in Harrow by 2.2% during the third quarter. State Street Corp now owns 730,973 shares of the company's stock valued at $32,865,000 after acquiring an additional 15,554 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Harrow during the 3rd quarter worth about $1,469,000. Institutional investors and hedge funds own 72.76% of the company's stock.

Remove Ads

Harrow Stock Down 2.4 %

Shares of NASDAQ HROW traded down $0.63 during trading on Tuesday, hitting $25.97. 347,911 shares of the company traded hands, compared to its average volume of 453,195. The firm has a market capitalization of $924.92 million, a price-to-earnings ratio of -27.61 and a beta of 0.69. The business's fifty day moving average is $28.76 and its 200 day moving average is $37.86. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. Harrow, Inc. has a fifty-two week low of $9.86 and a fifty-two week high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.14. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The business had revenue of $66.83 million for the quarter, compared to the consensus estimate of $66.01 million. Equities research analysts predict that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on HROW shares. B. Riley dropped their price objective on Harrow from $73.00 to $69.00 and set a "buy" rating on the stock in a research note on Wednesday, December 4th. HC Wainwright reissued a "buy" rating and issued a $57.00 price target on shares of Harrow in a research note on Monday.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.